The Pharma Tech Startup That’s Worth More Than Most Banks

Your Biotech Company Is Broken. Here’s a Delhi Kid Who’ll Fix It.

Indegene was founded in 1998. It’s been helping drug companies, biotech labs, and medical device makers do three things: develop products faster, get them approved quicker, and sell them harder. Think of them as the operations guy in your startup who isn’t brilliant but gets things done.

The company is essentially a business process outsourcer (BPO) with healthcare domain expertise and a tech platform. They handle marketing campaigns for pharma, manage regulatory submissions, run clinical trials, monitor drug safety, and increasingly, they build AI systems to do all of the above faster. The positioning has shifted from “grunt work BPO” to “AI-powered strategic partner.” Whether that’s marketing or reality remains to be seen. But the deals are real, the growth is real, and the stock is decidedly undervalued.

Founded by Manish Gupta (founder) and Rajesh Nair, the company went public in 2006, is now 25+ years old, and has quietly become one of the few Indian tech companies that’s scaled to $1+ billion in revenue while maintaining decent profitability. Yet somehow, it trades cheaper than companies that haven’t earned a rupee.

In the last 12 months, Indegene acquired BioPharm (a marketing tech company) for $104 million, scooped up Cake Group (an AI analytics firm) for EUR 8.5M, and acquired WARN & Co (UK regulatory firm) for GBP 3M. Management is betting that the future of pharma operations is AI-driven, centralized, and platformized. Let’s see if that thesis is worth ₹430 per share.

They Help Pharma Not Fail. For Money.

Indegene has four main revenue streams, each unglamorous and essential:

Enterprise Commercial Solutions (59% of FY24 revenue): Your drug isn’t selling. Indegene builds campaigns, manages omnichannel marketing, creates physician targeting strategies, and runs digital campaigns to push pills (legally). They offer brand strategy, go-to-market planning, pricing, and data analytics. Post-BioPharm acquisition, they now also own Tandem (omnichannel orchestration tech) and Invisage (audience intelligence), which means they can theoretically do end-to-end omnichannel marketing from a single platform.

Enterprise Medical Solutions (23%): Running regulatory submissions, managing medical affairs, handling adverse event reporting, and building “centers of excellence” where large pharma consolidate operations. Think of it as outsourced back-office for pharma’s most boring but critical functions.

Omnichannel Activation (12%): Digital reps, virtual sales teams, email campaigns, social media ads, and AI-driven targeting to HCPs (healthcare professionals). This is the “last-mile” distribution of pharma marketing—getting your message to the doctor through pixels.

Clinical & R&D Solutions (6% + others): Clinical trial recruitment, data management, regulatory submissions, and consultancy. Slow growth but mission-critical for biotech and emerging companies.

In plain English: Pharma companies are slow, bureaucratic, and global. Indegene plugs into their operations, automates grunt work, deploys tech, and lets pharma focus on discovering drugs. Pharma’s savings = Indegene’s growth. The economics are nearly recession-proof because regulatory requirements don’t go away.

When ₹94 Billion Looks Expensive